Publications by authors named "C StraSSburg"
Splanchnic vein thrombosis (SVT), which is particularly prevalent in myeloproliferative neoplasms (MPNs), has a multifactorial pathomechanism involving the anticoagulant protein C (PC) pathway. To better characterize the hypercoagulable state in SVT we assessed its key enzymes thrombin and activated PC (APC). The study population included 73 patients with SVT, thereof 36 MPN+, confirmed by bone marrow biopsy, 37 MPN-, and 30 healthy controls.
View Article and Find Full Text PDFLongitudinal Study of SARS-CoV-2 Vaccinations and Infections in Patients with Gastrointestinal Cancer: Stabilizing Immune Responses and Neutralizing Emerging Variants with Variant-Adapted Antigen Exposures.
Int J Mol Sci
December 2024
This longitudinal study examined how active gastrointestinal (GI) cancer types affect immune responses to SARS-CoV-2, focusing on the ability to neutralize the Omicron variants. Patients with GI cancer ( = 168) were categorized into those with hepatocellular carcinoma, hepatic metastatic GI cancer, non-hepatic metastatic GI cancer, and two control groups of patients with and without underlying liver diseases. Humoral and cellular immune responses were evaluated before and after Omicron antigen exposures.
View Article and Find Full Text PDFArticle Synopsis
- Immunotherapy combinations are the standard treatment for advanced hepatocellular carcinoma (HCC), with growing evidence supporting lenvatinib as a strong first-line option.
- A retrospective study analyzed 412 patients treated with either atezolizumab/bevacizumab (AZ/BV) or lenvatinib (LEN) across 18 European hospitals, revealing that those on AZ/BV experienced longer progression-free survival.
- Despite comparable survival rates between the two treatments overall, AZ/BV posed a higher risk of liver issues in patients with pre-existing liver function impairment, highlighting the need for careful patient monitoring.
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the risk of HCC development in ACLD.
View Article and Find Full Text PDFLenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer. In this study, we analyze the role of muscle loss in patients with advanced HCC treated with lenvatinib.
View Article and Find Full Text PDF